# Supplementary Materials

*for*

***Real-world Multi-country Study of BRCA1/2 Mutation Testing Among Adult Women With HER2-Negative Advanced Breast Cancer***

**Table S1** Baseline demographics and clinical characteristics by region among adult women with HER2-negative ABC; US and EU

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **US*****N* = 1285** |  | **EU5*****N* = 4876** |  |
|  | ***BRCA1/2* tested(*n* = 648)** | ***BRCA1/2* not tested****(*n* = 637)** | ***P*-valuea** | ***BRCA1/2* tested(*n* = 1048)** | ***BRCA1/2* not tested****(*n* = 3828)** | ***P*-valuea** |
| Mean age, years | 59.2 | 66.1 | < 0.0001 | 57.7 | 65.2 | < 0.0001 |
| Ethnicity, *n* (%) |  |  |  |  |  |  |
| White/Caucasian | 348 (54) | 380 (60) | 0.0325 | 920 (88) | 3464 (90) | 0.0127 |
| African American | 131 (20) | 119 (19) | 0.53 | N/A | N/A | N/A |
| Hispanic/Latino | 63 (10) | 54 (8) | 0.50 | N/A | N/A | N/A |
| Other | 106 (16) | 84 (13) | 0.12 | 128 (12)b | 364 (10)b | 0.0127 |
| HR status, *n* (%) |  |  |  |
| HR+/HER2- | 416 (64) | 547 (86) | < 0.0001 | 651 (62) | 2,997 (78) | < 0.0001 |
| TNBC | 211 (33) | 84 (13) | < 0.0001 | 366 (35) | 754 (20) | < 0.0001 |
| Unknown | 21 (3) | 6 (1) | 0.0055 | 31 (3) | 77 (2) | 0.07 |
| Premenopausal, *n* (%) | 105 (16) | 36 (6) | < 0.0001 | 248 (24) | 235 (6) | < 0.0001 |
| Family history of breast or ovarian cancer, *n* (%) |  |  |  |
| Yes | 136 (21) | 57 (9) | < 0.0001 | 217 (21) | 296 (8) | < 0.0001 |
| No | 440 (68) | 491 (77) | < 0.0001 | 731 (70) | 3,071 (80) | < 0.0001 |
| Unknown | 72(11) | 89 (14) | 0.13 | 100 (10) | 461 (12) | 0.025 |
| Currently employed, *n* (%) | 229 (35) | 191 (30) | 0.0432 | 244 (23) | 574 (15) | < 0.0001 |
| Insurance, *n* (%)c |  |  |  |  |  |  |
| Medicaid | 83 (13) | 39 (6) | < 0.0001 | – | – | – |
| Medicare | 195 (30) | 340 (53) | < 0.0001 | – | – | – |
| Commercial | 312 (48) | 214 (34) | < 0.0001 | – | – | – |
| No insurance coverage | 9 (1) | 9 (1) | 1.00 | – | – | – |
| Other/unknown | 49 (8) | 35 (5) | 0.14 | – | – | – |

a*t* test for continuous variables and Fisher’s exact test for categorical variables.

bOther includes all other ethnicities excluding white/Caucasian.

cNot relevant for EU5 countries.

ABC, advanced breast cancer; *BRCA1/2*, *breast cancer susceptibility gene 1* or *2*; EU5, France, Germany, Italy, Spain and the UK;
HER2, human epidermal growth factor receptor 2; HER2-, HER2-negative; HR, hormone receptor; HR+, HR-positive; N/A, not available; TNBC, triple-negative breast cancer.